v3.26.1
Document and Entity Information
May 17, 2026
Cover [Abstract]  
Amendment Flag true
Entity Central Index Key 0001662774
Document Type 8-K/A
Document Period End Date May 17, 2026
Entity Registrant Name QUINCE THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38890
Entity Tax Identification Number 90-1024039
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 273
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (415)
Local Phone Number 910-5717
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol QNCX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Description This Amendment No 1 to the Current Report on Form 8-K (the “Original Filing”) that was originally filed with the Securities and Exchange Commission on May 18, 2026 is being filed solely to replace the press release included as Exhibit 99.2 to the Original Filing, to update the table under the heading “LAM-001 Phase 2a PH Efficacy” to replace 35.3% and 28.1% with -35.3% and -28.1%, respectively. No other changes have been made to the Original Filing.